Suppr超能文献

刑事司法系统转介的阿片类药物使用障碍治疗中药物使用的差异。

Disparities in Medication Use for Criminal Justice System-Referred Opioid Use Disorder Treatment.

机构信息

Department of Health Policy and Management, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.

Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.

出版信息

JAMA Health Forum. 2024 Sep 6;5(9):e242807. doi: 10.1001/jamahealthforum.2024.2807.

Abstract

IMPORTANCE

Individuals with opioid use disorder (OUD) and criminal justice system involvement experience high rates of overdose death. Historical data point to limited use of medications for opioid use disorder (MOUD) in criminal justice system-referred treatment for OUD as playing a role. However, how MOUD use among those referred to treatment by the criminal justice system has changed relative to other referral sources over time is still unclear, as well as how it varies across states.

OBJECTIVE

To examine disparities in the use of MOUD between individuals referred to treatment by the criminal justice system compared to other referral sources over time.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included admissions to specialty substance use treatment facilities for OUD in the national Treatment Episodes Dataset-Admissions from 2014 to 2021. Logistic regression models were used to examine trends in the probability of MOUD use among individuals with and without criminal justice referrals for OUD treatment, as well as any differential trends by state. The data were analyzed from September 2023 to August 2024.

MAIN OUTCOME AND MEASURE

The main outcome was the probability that treatment for individuals with OUD included MOUD.

RESULTS

A total of 3 235 445 admissions were analyzed in the study data. Among individuals referred to OUD treatment by the criminal justice system, the probability that treatment included MOUD increased by 3.42 percentage points (pp) (95% CI, 3.37 pp to 3.47 pp) annually from 2014 to 2021. This was faster than the increase in the probability of MOUD use for noncriminal justice-referred admissions (2.49 pp [95% CI, 2.46 pp to 2.51 pp) and reduced, but did not eliminate, disparities in MOUD use between individuals with and without criminal justice system-referred treatment. In 2021, only 33.6% of individuals in criminal justice system-referred treatment received MOUD, 15.6 pp lower than for individuals referred to treatment by other sources. Trends in the probability of MOUD use varied substantially for individuals in criminal justice system-referred treatment across states, but very few experienced enough growth to eliminate this disparity.

CONCLUSIONS AND RELEVANCE

The results of this cross-sectional study suggest that targeted efforts to address persistent disparities in MOUD use among those with OUD and criminal justice system involvement are needed to address the poor health outcomes experienced by this population.

摘要

重要性

患有阿片类药物使用障碍 (OUD) 且与刑事司法系统有牵连的个体经历过高的过量死亡风险。历史数据表明,在刑事司法系统转介的治疗 OUD 中,阿片类药物使用障碍 (MOUD) 的药物使用有限。然而,随着时间的推移,相对于其他转介来源,转介至治疗的个体中 MOUD 的使用情况如何发生了变化,以及这种变化在各州之间如何变化,目前仍不清楚。

目的

检查随着时间的推移,与其他转介来源相比,通过刑事司法系统转介接受治疗的个体中 MOUD 的使用情况存在哪些差异。

设计、地点和参与者:这项横断面研究包括 2014 年至 2021 年全国治疗阶段数据集-入院中 OUD 的专科物质使用治疗设施的入院情况。使用逻辑回归模型检查 OUD 治疗中有无刑事司法转介的个体中 MOUD 使用的概率趋势,以及各州的任何差异趋势。数据分析于 2023 年 9 月至 2024 年 8 月进行。

主要结果和措施

主要结果是评估治疗 OUD 的个体中是否包含 MOUD。

结果

在研究数据中分析了 3235445 例入院。在通过刑事司法系统转介接受 OUD 治疗的个体中,从 2014 年到 2021 年,治疗中包含 MOUD 的概率每年增加 3.42 个百分点(95%CI,3.37 个百分点至 3.47 个百分点)。这快于非刑事司法转介入院的 MOUD 使用概率的增加(2.49 个百分点 [95%CI,2.46 个百分点至 2.51 个百分点),并且减少了,但并没有消除刑事司法系统转介治疗的个体与未转介治疗的个体之间在 MOUD 使用方面的差异。2021 年,只有 33.6%的刑事司法系统转介治疗的个体接受了 MOUD,比其他来源转介治疗的个体低 15.6 个百分点。在各州,刑事司法系统转介治疗的个体中 MOUD 使用概率的趋势差异很大,但很少有州的增长足以消除这种差异。

结论和相关性

这项横断面研究的结果表明,需要针对那些患有 OUD 且与刑事司法系统有牵连的个体中 MOUD 使用方面持续存在的差异,开展有针对性的努力,以解决这一人群面临的不良健康结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bfd/11380100/13e3cf75af90/jamahealthforum-e242807-g001.jpg

相似文献

1
Disparities in Medication Use for Criminal Justice System-Referred Opioid Use Disorder Treatment.
JAMA Health Forum. 2024 Sep 6;5(9):e242807. doi: 10.1001/jamahealthforum.2024.2807.
2
Factors associated with receipt of medication for opioid use disorder among pregnant individuals entering treatment programs in the U.S.
Int J Drug Policy. 2024 Apr;126:104342. doi: 10.1016/j.drugpo.2024.104342. Epub 2024 Mar 13.
4
Medicaid Expansion Increased Medications For Opioid Use Disorder Among Adults Referred By Criminal Justice Agencies.
Health Aff (Millwood). 2021 Apr;40(4):562-570. doi: 10.1377/hlthaff.2020.01251.
5
State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015.
Drug Alcohol Depend. 2020 Jan 1;206:107654. doi: 10.1016/j.drugalcdep.2019.107654. Epub 2019 Nov 2.
6
Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
JAMA Netw Open. 2022 Mar 1;5(3):e223821. doi: 10.1001/jamanetworkopen.2022.3821.
7
Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.
Drug Alcohol Depend. 2021 Oct 1;227:108927. doi: 10.1016/j.drugalcdep.2021.108927. Epub 2021 Jul 28.
8
Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
J Subst Use Addict Treat. 2023 Jun;149:209051. doi: 10.1016/j.josat.2023.209051. Epub 2023 Apr 19.
9
State level variation in substance use treatment admissions among criminal legal-referred individuals.
Drug Alcohol Depend. 2022 Nov 1;240:109651. doi: 10.1016/j.drugalcdep.2022.109651. Epub 2022 Oct 1.

引用本文的文献

本文引用的文献

1
Racial Inequality in Receipt of Medications for Opioid Use Disorder.
N Engl J Med. 2023 May 11;388(19):1779-1789. doi: 10.1056/NEJMsa2212412.
2
Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data.
J Subst Use Addict Treat. 2023 Apr;147:208971. doi: 10.1016/j.josat.2023.208971. Epub 2023 Feb 10.
3
Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers.
J Subst Use Addict Treat. 2023 Apr;147:208950. doi: 10.1016/j.josat.2022.208950. Epub 2023 Jan 13.
4
Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.
Drug Alcohol Depend. 2022 Mar 1;232:109291. doi: 10.1016/j.drugalcdep.2022.109291. Epub 2022 Jan 11.
5
Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021.
JAMA Netw Open. 2021 Dec 1;4(12):e2138807. doi: 10.1001/jamanetworkopen.2021.38807.
6
The impact of the opioid crisis on U.S. state prison systems.
Health Justice. 2021 Jul 24;9(1):17. doi: 10.1186/s40352-021-00143-9.
9
Medicaid Expansion Increased Medications For Opioid Use Disorder Among Adults Referred By Criminal Justice Agencies.
Health Aff (Millwood). 2021 Apr;40(4):562-570. doi: 10.1377/hlthaff.2020.01251.
10
The relationship between incarceration history and overdose in North America: A scoping review of the evidence.
Drug Alcohol Depend. 2020 Aug 1;213:108088. doi: 10.1016/j.drugalcdep.2020.108088. Epub 2020 May 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验